Objective To evaluate telmasartan on cardiac function and brain natriuretic peptide (BNP) patients with chronic heart failure (CHF).
Methods We enrolled 120 patients with CHF, NYHAI--III, age 30–79 (61.25±10.18) years. All the patients were randomly assigned to 2 groups: standard therapy group (n=60, receiving ACEI, digoxin, diuretic, β-blcoks), telmasartan treatment group (n=60 receiving telmasartan in addition to the standard therapy). These patients were treated for 1 years, and plasma levels of BNP and left ventiricular ejection fraction (LVEF) were measured before and after treartments.
Results No significant differences in baseline characteristics were observed between the two groups. After treatment, BNP plasma levels both decreased and LVEF increased significantly in two groups. BNP plasma levels in telmasartan treatment group were lower than that in standard group and LVEF higher at 1 year follow-up.
Conclusion Telmasartan in addition to the standard therapy can improve the cardiac function and desease BNP plasma levels.